Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension.

Published

Journal Article

BACKGROUND: Portopulmonary hypertension is a known complication in the liver transplant candidate. Intravenous epoprostenol has been demonstrated to decrease pulmonary artery pressures and possibly remodel right ventricle geometry. METHODS: In this report, we document the efficacy of inhaled aerosolized epoprostenol in a patient with portopulmonary hypertension. The effect was of rapid onset and offset. RESULTS: After 10 min of delivery, mean pulmonary artery pressure decreased 26%; cardiac output increased by 22%; pulmonary vascular resistance decreased by 42%; and the transpulmonary gradient decreased by 29%. There were no untoward side effects. CONCLUSION: The inhaled route of delivery of epoprostenol is potential alternative for the acute therapy of portpulmonary hypertension.

Full Text

Duke Authors

Cited Authors

  • Schroeder, RA; Rafii, AA; Plotkin, JS; Johnson, LB; Rustgi, VK; Kuo, PC

Published Date

  • August 15, 2000

Published In

Volume / Issue

  • 70 / 3

Start / End Page

  • 548 - 550

PubMed ID

  • 10949204

Pubmed Central ID

  • 10949204

International Standard Serial Number (ISSN)

  • 0041-1337

Language

  • eng

Conference Location

  • United States